RareKids-CAN_From Evidence to Access- Advancing Pediatric Rare Disease Drug Availability in Canada

Date

Feb 04 2026

Time

17:00 - 18:00

Labels

Virtual

RareKids-CAN | From Evidence to Access: Advancing Pediatric Rare Disease Drug Availability in Canada

How can Canada better translate evidence into real-world access for children living with rare diseases

Join RareKids-CAN for an in-depth discussion on the evolving role of health technology assessment and reimbursement policy in improving access to pediatric rare disease care.

Date: February 4, 2026
Time:
5:00–6:00 PM EST
Virtual (Zoom)

Moderators:

  • Maryam Oskoui MD, Professor, McGill Faculty of Medicine and Health Sciences, RareKids-CAN HTA Sub-Platform Co-Lead
  • Marc-André Gagnon PhD, Professor, School of Public Policy & Administration, Carleton University

Speakers:

  • Matthew McDonald PhD, Director, Pharmaceutical Policy and HTA, Canada’s Drug Agency
  • Douglas Clark, Agathon Consulting; former Executive for Patented Medicine Prices Review Board and Pan-Canadian Pharmaceutical Alliance